are categorised as follows: very common common from to <10%; uncommon from 10%; 1% †Frequencies 0.1% to <1%; rare from 0.01% to <0.1%) Adverse Events Reported in Comparative Therapeutic Studies 305 and 307/602 at a rate of  1% Possibly Related to Therapy or Causality Unknown Protocol 305 Protocol 307/602 Voriconazole vs Voriconazole vs Conventional Fluconazole Amphotericin B (IV/oral (oral therapy) therapy) Vori Fluc Vori Ampho B† N = 200 N =191 N =196 N = 185 N (%) N (%) N (%) N (%)
†Frequencies are categorised as follows: very common 10%; common from 1% to <10%; uncommon from 0.1% to <1%; rare from 0.01% to <0.1%) Adverse Events Reported in Comparative Therapeutic Studies 305 and 307/602 at a rate of  1% Possibly Related to Therapy or Causality Unknown Protocol 305 Voriconazole vs Fluconazole (oral therapy) Protocol 307/602 Voriconazole vs Conventional Amphotericin B (IV/oral therapy) Vori N = 200 N (%) Fluc N =191 N (%) Vori N =196 N (%) Ampho B† N = 185 N (%)
auspar-voriconazole-170629-pi.docx